![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for $1,500,000 over 2 years to support the modification of their proprietary Total Holographic Characterization® technology to meet the specific needs of the biologics pharmaceutical industry.
These highly competitive grants are intended to stimulate technological innovation and commercialization for small businesses.
Although a beta version of Spheryx’s xSight instrument for Total Holographic Characterization® is currently available for sale to select customer/partner companies, xSight will require additional functionality to meet the needs of the biologics industry. Critical innovations funded by this grant include high volume sample handling, high-speed flow, and detailed three-dimensional structures of protein aggregates to distinguish them from other contaminants.
Dr. Laura Philips, Founder, President and CEO, commented, “This Phase II SBIR award will enable us to deliver a powerful tool for the biologics industry. Enhancement of xSight will support their efforts to create the next generation of biologic pharmaceutical products and ensure that they are safe for consumers.”
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization® of colloidal materials. Spheryx’s proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials’ characteristics. Applications include R&D, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs.
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially.
